Human gene transfer protocols, United States and worldwide, 1988–2005

	U.S. total	%	World total*	%
Cancer	436	65	675	66
Immunotherapy/in vivo transduction	159
Immunotherapy/in vitro transduction	129
Pro-drug/HSV-TK and ganciclovir	45
Tumor suppressor gene	38
Vector-directed cell lysis	28
Other therapeutic approaches	37
Monogenic Diseases	60	9	93	9
Cystic fibrosis	23
Severe combined immunodeficiency (SCID)	6
Hemophilia	5
Fanconi anemia	4
Other monogenic diseases	22
Cardiovascular Disease	55	8	85	8
Peripheral artery disease	29
Coronary artery disease	21
Other cardiovascular disease	5
Infectious Disease	42	6	68	7
Human immunodeficiency virus	39
Other viral diseases	3
Central Nervous System Diseases	5	<1	5	<1
(Alzheimer’s disease, Parkinson’s disease, epilepsy)
Other Diseases & Disorders	19	3	26	3
(arthritis, autoimmune disease, bone fracture, cubital tunnel syndrome, erectile dysfunction, eye disorders, intractable pain, peripheral neuropathy, ulcer)
Marking and Nontherapeutic Uses	50	7	68	7
Total gene transfer protocols	667		1,020

HSV-TK=herpes simplex thymidine kinase.

^*Includes United States.

SOURCES: RECOMBINANT DNA ADVISORY COMMITTEE. Available at: «http://www4.od.nih.gov/oba/rac/PROTOCOL.pdf»;

GENE THERAPY CLINICAL TRIALS WORLDWIDE. Available at: «http://www.wiley.co.uk/genmed/clinical».